Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 772 across all filing types
Latest filing 2026-04-30 Capital/Financing Update
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the approval of an agreement to transfer a business division (ophthalmic division) from Indoco Remedies Limited to Sunways India. It is addressed to stock exchanges and includes details about the transaction, strategic rationale, and company background. There are no financial statements, regulatory certifications, or detailed financial data presented. The document is an announcement of a corporate transaction rather than a full merger filing or detailed merger proxy statement. It does not fit the detailed M&A filings (MA) or merger proxy statements but is more of a general corporate announcement about a business transfer. Given the nature of the document as a press release announcing a business transfer agreement, the most appropriate classification is Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including significant business transfers or divestments.
2026-04-30 English
Agreements
Capital/Financing Update Classification · 95% confidence The document is a formal announcement addressed to stock exchanges regarding the outcome of a Board Meeting where the company approved an Agreement to Transfer Business (ATB) involving the sale of its Ophthalmic Division. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content includes detailed information about the transaction, buyer details, financial figures related to the division being sold, and regulatory compliance disclosures. The document is not a full financial report, audit, or earnings release but rather a regulatory announcement about a significant corporate transaction approved by the Board. It does not contain financial statements or detailed financial analysis but provides information required for stock exchange disclosure. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a significant business transfer impacting the company's capital structure and operations.
2026-04-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is a notification from Indoco Remedies Limited about an upcoming earnings conference call scheduled for May 7, 2026, to discuss the audited financial results for the quarter and year ended March 31, 2026. It includes details about the call, participants, and dial-in information. The document does not contain the financial results themselves but is an announcement of the event where these results will be discussed. According to the classification rules, such notifications are classified as Call Transcript (CT) only if they contain the full transcript of the call. Since this is only an announcement of the call, it does not fit CT. It is also not an earnings release (ER) because it does not contain financial highlights. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about the earnings call. However, given the specific nature of the announcement about the earnings conference call, the most appropriate classification is Call Transcript (CT) with low confidence because it is related to the call but not the transcript itself. But per rules, announcements of calls are not CT. Therefore, the correct classification is Regulatory Filings (RNS) with high confidence.
2026-04-27 English
Board Meeting — Board Meeting Intimation
Regulatory Filings Classification · 95% confidence The document is an XBRL filing related to a Board Meeting scheduled for May 7, 2026, by Indoco Remedies Limited. The agenda includes financial results and dividend declaration. The results are audited, standalone and consolidated, for the yearly period ended March 2026. The document length is 2648 characters, which is relatively short and appears to be an intimation or announcement rather than the full financial report itself. It does not contain detailed financial statements or substantive financial data but rather metadata and meeting details. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a formal announcement/intimation of the board meeting and related financial results and dividend, not the full Annual Report or Earnings Release.
2026-04-27 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short formal letter addressed to stock exchanges, providing an update on the completion of a U.S. FDA Pre-Approval Inspection at the company's testing facility. It references compliance with SEBI Listing Obligations Regulation 30, which mandates disclosure of material events. The content is an announcement of an event (inspection outcome) rather than a financial report, management discussion, or detailed filing. The document length is only 1302 characters, indicating it is a brief announcement. There is no financial data, no voting results, no management changes, no earnings information, or other report content. Therefore, it fits best as a Regulatory Filing (RNS) which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2026-04-13 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a compliance certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming compliance for the quarter ended 31st March 2026. It is addressed to stock exchanges and signed by the company secretary and the registrar and transfer agent. The content is a certification of regulatory compliance related to securities dematerialisation and does not contain financial statements or detailed financial data. The document length is 3129 characters, which is relatively short and primarily serves as a certification letter. According to the Certification Rule, such officer certifications or compliance certificates should be classified as Regulatory Filings (RNS) rather than as financial reports or other categories.
2026-04-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.